Nuvectis Pharma (NVCT) Projected to Post Quarterly Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) is expected to announce its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 9:30 AM ET.

Nuvectis Pharma (NASDAQ:NVCT) last announced its earnings results on Wednesday, February 11th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.05). On average, analysts expect Nuvectis Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvectis Pharma Stock Performance

Shares of NVCT stock opened at $8.54 on Monday. Nuvectis Pharma has a 1 year low of $5.55 and a 1 year high of $11.15. The firm’s fifty day simple moving average is $8.48 and its 200 day simple moving average is $7.76. The firm has a market capitalization of $236.28 million, a P/E ratio of -6.47 and a beta of -0.11.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuvectis Pharma in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.00.

Institutional Investors Weigh In On Nuvectis Pharma

Institutional investors and hedge funds have recently bought and sold shares of the business. Barclays PLC increased its holdings in Nuvectis Pharma by 31.3% in the 4th quarter. Barclays PLC now owns 24,185 shares of the company’s stock valued at $183,000 after buying an additional 5,760 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Nuvectis Pharma by 15.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 44,022 shares of the company’s stock valued at $332,000 after buying an additional 6,040 shares during the period. Jane Street Group LLC bought a new stake in Nuvectis Pharma in the 1st quarter valued at $413,000. Vanguard Group Inc. increased its holdings in Nuvectis Pharma by 4.8% in the 3rd quarter. Vanguard Group Inc. now owns 698,708 shares of the company’s stock valued at $4,206,000 after buying an additional 31,903 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Nuvectis Pharma in the 2nd quarter valued at $53,000. Institutional investors own 96.77% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.